Log In
Print
BCIQ
Print
Print this Print this
 

APO010

  Manage Alerts
Collapse Summary General Information
Company Onxeo S.A.
DescriptionRecombinant fusion protein derived from the pro-apoptotic human Fas ligand (FasL) protein
Molecular Target Fas receptor (CD95)
Mechanism of ActionFas receptor (CD95) agonist
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Oncology Venture ApS


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today